Fuji Pharma has agreed with JCR Pharmaceuticals to terminate their joint development contract for JR-013, a drug candidate for treating renal anemia. Since November 2004, the two companies have collaborated in R&D for the candidate. However, the two companies have disagreed on the direction of development, future budget plans and related rights. Fuji Pharma will halt the development of JR-013. Meanwhile, JCR Pharmaceuticals will conduct clinical trials as originally planned with a view to forming a partnership with other companies.
Japan Corporate News Network (http://www.japancorp.net/Article.Asp?Art_ID=11310)